These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors. Keshgegian AA Arch Pathol Lab Med; 1994 Mar; 118(3):240-4. PubMed ID: 8135626 [TBL] [Abstract][Full Text] [Related]
3. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
4. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012 [TBL] [Abstract][Full Text] [Related]
5. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer. Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189 [TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046 [TBL] [Abstract][Full Text] [Related]
7. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528 [TBL] [Abstract][Full Text] [Related]
8. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579 [TBL] [Abstract][Full Text] [Related]
9. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639 [TBL] [Abstract][Full Text] [Related]
10. Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma. Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K Anticancer Res; 1991; 11(5):1701-6. PubMed ID: 1768039 [TBL] [Abstract][Full Text] [Related]
11. [Steroid receptors and breast carcinoma]. Pasić R; Dulbegović B; Softić D; Wittlif JL Med Pregl; 1991; 44(1-2):48-51. PubMed ID: 1870463 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554 [TBL] [Abstract][Full Text] [Related]
13. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer. Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125 [TBL] [Abstract][Full Text] [Related]
14. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance]. Yang JQ; Chen L; Xing TY Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828 [TBL] [Abstract][Full Text] [Related]
15. Progesterone and estrogen receptors as prognostic variables in breast cancer. Mason BH; Holdaway IM; Mullins PR; Yee LH; Kay RG Cancer Res; 1983 Jun; 43(6):2985-90. PubMed ID: 6850609 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information. Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596 [TBL] [Abstract][Full Text] [Related]
17. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477 [TBL] [Abstract][Full Text] [Related]
18. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374 [TBL] [Abstract][Full Text] [Related]
19. [Immunohistochemical characteristics of mammary carcinomas with estrogen-negative and progesterone-positive receptors]. Sundblad AS; Caprarulo L Medicina (B Aires); 1996; 56(6):683-9. PubMed ID: 9284572 [TBL] [Abstract][Full Text] [Related]
20. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan. Sharif MA; Mamoon N; Mushtaq S; Khadim MT J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]